Author

Marc Lecoultre

Observed names: Lecoultre, Marc, M. Lecoultre

Institution: International Telecommunication Union

Observed institutions: University of Geneva, International Telecommunication Union, University Hospital Zurich, University Hospital of Geneva, Swiss Cancer Center Léman, University of Hong Kong

ORCID: 0009-0006-5583-3378

Observed ORCID: 0009-0006-5583-3378

OpenAlex ID: A5062261477

Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review

2020 · Marc Lecoultre, Valérie Dutoit, et al. · Journal for ImmunoTherapy of Cancer · 238

Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages

2024 · Stoyan Tankov, Marija Petrovic, et al. · Cell Communication and Signaling · 48

Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade

2025 · Felipe I. Espinoza, Stoyan Tankov, et al. · Cellular and Molecular Life Sciences · 26

Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy

2024 · Marc Lecoultre, Paul R. Walker, et al. · Clinical and Experimental Medicine · 24

Radio-chemotherapy of glioblastoma cells promotes phagocytosis by macrophages in vitro

2023 · Marc Lecoultre, Sylvie Chliate, et al. · Radiotherapy and Oncology · 11

Abstract LB-C12: Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer

2019 · Paul McSheehy, Felix Bachmann, et al. · Molecular Cancer Therapeutics · 6

Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models

2022 · Mahmoud El Shemerly, Elisa Zanini, et al. · Anti-Cancer Drugs · 3

The TAC-GReD trial: The combination of talazoparib and carboplatin in DNA damage repair deficient recurrent high-grade glioma.

2024 · Marc Lecoultre, Peter Yat Ming Woo, et al. · Journal of Clinical Oncology · 2

Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors”

2025 · Marc Lecoultre, Aya El Helali · Journal for ImmunoTherapy of Cancer · 1

668P The Impact of MTAP loss on response to immune checkpoint inhibitors in stage IV NSCLC: A prospective real-world analysis

2024 · A. El-Helali, E.Y-L. Ko, et al. · Annals of Oncology · 1

MAGIC: an international network for evaluating generative artificial intelligence in global health

2026 · Rui Yang, Weihao Xuan, et al. · Nature Medicine

Biom-63. Long-term Survival and Molecular Characterization of Idh-wildtype Glioblastoma in an Asian Cohort

2024 · Wing Lun Lee, Elaine Yee-Ling Ko, et al. · Neuro-Oncology

Real-world data based on PD-L1 expression in early-stage NSCLC in an east-Asian patient population: A 10-year follow-up study.

2024 · Ji Hyung Hong, Elaine Yee-Ling Ko, et al. · Journal of Clinical Oncology

Works count: 25

Citation count: 360

H-index: 6

I10-index: 5